Sclerotherapy for Venous Malformations of Head and Neck: Systematic Review and Meta-Analysis

We performed a systematic review and meta-analysis of studies performing sclerotherapy for treatment of venous malformations (VMs) of the face, head and neck. It is our hope that data from this study could be used to better inform providers and patients regarding the benefits and risks of percutaneous sclerotherapy for treatment of face, head and neck VMs. We searched PubMed, MEDLINE, and EMBASE from 2000–2018 for studies evaluating the safety and efficacy of percutaneous sclerotherapy of neck, face and head VMs. Two independent reviewers selected studies and abstracted data. The primary outcomes were complete and partial resolution of the VM. Data were analyzed using random-effects meta-analysis. Thirty-seven studies reporting on 2,067 patients were included. The overall rate of complete cure following percutaneous sclerotherapy with any agent was 64.7% (95% confidence interval [CI], 57.4–72.0%). Sodium tetradecyl sulfate had the lowest complete cure rate at 55.5% (95% CI, 36.1–74.9%) while pingyangmycin had the highest cure rate at 82.9% (95% CI, 71.1–94.7%). Overall patient satisfaction rates were 91.0% (95% CI, 86.1–95.9%). Overall quality of life improvement was 78.9% (95% CI, 67.0–90.8%). Overall permanent morbidity/mortality was 0.8% (95% CI, 0.3–1.3%) with no cases of mortality. Our systematic review and meta-analysis of 37 studies and over 2,000 patients found that percutaneous sclerotherapy is a very safe and effective treatment modality for treatment of VMs of the head, neck and face.

Download Full-text

Ethanol sclerotherapy of head and neck venous malformations

Einstein (São Paulo) ◽

10.1590/s1679-45082014ao2844 ◽

2014 ◽

Vol 12 (2) ◽

pp. 181-186 ◽

Cited By ~ 14

Author(s):

José Luiz Orlando ◽

José Guilherme Mendes Pereira Caldas ◽

Heloisa Galvão do Amaral Campos ◽

Kenji Nishinari ◽

Mariana Krutman ◽

...

Keyword(s):

Head And Neck ◽

Complete Resolution ◽

Intralesional Injection ◽

Low Doses ◽

Venous Malformations ◽

Ethanol Sclerotherapy ◽

Percutaneous Sclerotherapy ◽

Effective Treatment Modality ◽

Median Period ◽

The Face

Objective This retrospective study evaluated the results of sclerotherapy with low doses of ethanol for treatment of head and neck venous malformations.Methods We treated 51 patients, 37 females. Median age was 23 years. Patients were treated with percutaneous intralesional injection of alcohol every two weeks and followed up prospectively for a median period of 18 months. Most lesions affected the face and cosmetic disfigurement was the most frequent complaint.Results We performed a median of 7 sessions of sclerotherapy. Complete resolution or improvement was observed in 48 patients presented. Five cases of small skin ulceration, two cases of hyperpigmentation and two of paresthesia were documented; all of them were treated conservatively.Conclusion Percutaneous sclerotherapy with low doses of ethanol is a safe and effective treatment modality for venous malformations affecting the head and neck.

Download Full-text

Faculty Opinions recommendation of Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718141083.793502027 ◽

2014 ◽

Author(s):

Giulio Cantu ◽

Stefano Riccio ◽

Sarah Colombo

Keyword(s):

Systematic Review ◽

Head And Neck Cancer ◽

Cancer Treatment ◽

Head And Neck ◽

Neck Cancer ◽

Meta Analysis ◽

Volume Outcome

Download Full-text

Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2020.102984 ◽

2020 ◽

Vol 153 ◽

pp. 102984 ◽

Cited By ~ 2

Author(s):

Ashley Lau ◽

Wei-fa Yang ◽

Kar-Yan Li ◽

Yu-xiong Su

Keyword(s):

Systematic Review ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Systemic Therapy ◽

Meta Analysis ◽

Neck Squamous Cell Carcinoma

Download Full-text

Incidence of Oral Mucositis in Patients Undergoing Head and Neck Cancer Treatment: Systematic Review and Meta-Analysis

Medical Sciences Forum ◽

10.3390/msf2021005023 ◽

2021 ◽

Vol 5 (1) ◽

pp. 23

Author(s):

Raquel Pacheco ◽

Maria Alzira Cavacas ◽

Paulo Mascarenhas ◽

Pedro Oliveira ◽

Carlos Zagalo

Keyword(s):

Systematic Review ◽

Head And Neck Cancer ◽

Oral Health ◽

Cancer Treatment ◽

Head And Neck ◽

Neck Cancer ◽

Oral Mucositis ◽

Negative Impact ◽

Meta Analysis ◽

Incidence Rates

This systematic review and meta-analysis aimed to assess the literature about the incidence of oral mucositis and its degrees (mild, moderate, and severe), in patients undergoing head and neck cancer treatment (radiotherapy, chemotherapy, and surgery). Addressing this issue is important since oral mucositis has a negative impact on oral health and significantly deteriorates the quality of life. Therefore, a multidisciplinary team, including dentists, should be involved in the treatment. The overall oral mucositis incidence was 89.4%. The global incidence for mild, moderate, and severe degrees were 16.8%, 34.5%, and 26.4%, respectively. The high incidence rates reported in this review point out the need for greater care in terms of the oral health of these patients.

Download Full-text

Mortality due to cancer treatment delay: systematic review and meta-analysis

BMJ ◽

10.1136/bmj.m4087 ◽

2020 ◽

pp. m4087 ◽

Cited By ~ 5

Author(s):

Timothy P Hanna ◽

Will D King ◽

Stephane Thibodeau ◽

Matthew Jalink ◽

Gregory A Paulin ◽

...

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Confidence Interval ◽

Cancer Treatment ◽

Head And Neck ◽

Adjuvant Radiotherapy ◽

Systemic Treatment ◽

Meta Analysis ◽

Treatment Delay ◽

Hazard Ratio

Abstract Objective To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways. Design Systematic review and meta-analysis. Data sources Published studies in Medline from 1 January 2000 to 10 April 2020. Eligibility criteria for selecting studies Curative, neoadjuvant, and adjuvant indications for surgery, systemic treatment, or radiotherapy for cancers of the bladder, breast, colon, rectum, lung, cervix, and head and neck were included. The main outcome measure was the hazard ratio for overall survival for each four week delay for each indication. Delay was measured from diagnosis to first treatment, or from the completion of one treatment to the start of the next. The primary analysis only included high validity studies controlling for major prognostic factors. Hazard ratios were assumed to be log linear in relation to overall survival and were converted to an effect for each four week delay. Pooled effects were estimated using DerSimonian and Laird random effect models. Results The review included 34 studies for 17 indications (n=1 272 681 patients). No high validity data were found for five of the radiotherapy indications or for cervical cancer surgery. The association between delay and increased mortality was significant (P<0.05) for 13 of 17 indications. Surgery findings were consistent, with a mortality risk for each four week delay of 1.06-1.08 (eg, colectomy 1.06, 95% confidence interval 1.01 to 1.12; breast surgery 1.08, 1.03 to 1.13). Estimates for systemic treatment varied (hazard ratio range 1.01-1.28). Radiotherapy estimates were for radical radiotherapy for head and neck cancer (hazard ratio 1.09, 95% confidence interval 1.05 to 1.14), adjuvant radiotherapy after breast conserving surgery (0.98, 0.88 to 1.09), and cervix cancer adjuvant radiotherapy (1.23, 1.00 to 1.50). A sensitivity analysis of studies that had been excluded because of lack of information on comorbidities or functional status did not change the findings. Conclusions Cancer treatment delay is a problem in health systems worldwide. The impact of delay on mortality can now be quantified for prioritisation and modelling. Even a four week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers. Policies focused on minimising system level delays to cancer treatment initiation could improve population level survival outcomes.

Download Full-text